UroGen Pharma Welcomes New Board Member Kate Falberg

Ra’anana, Israel, April 24, 2017: UroGen Pharma Ltd., a privately held, clinical stage biopharmaceutical company that is developing advanced non-surgical treatments to address unmet needs in the field of uro-oncology, announced today the appointment of Kathryn “Kate” Falberg to its … Continue reading

Posted in News | Leave a comment

UroGen Pharma Announces Enrollment of First Patient in Phase 3 Clinical Trial of MitoGel™ for Treatment of Low-Grade Upper Tract Urothelial Carcinoma

RA’ANANA, Israel and NEW YORK, April 03, 2017 (GLOBE NEWSWIRE) — UroGen Pharma Ltd., a privately held, clinical-stage biopharmaceutical company that is developing advanced non-surgical treatments to address unmet needs in the field of uro-oncology, announced today that the first … Continue reading

Posted in News | Leave a comment

UroGen Pharma Announces FDA Acceptance of Investigational New Drug Application for MitoGel, a Novel Sustained Release Formulation of Mitomycin C, for the Treatment of Low-Grade Upper Tract Urothelial Carcinoma

-Plans to Initiate Single Pivotal, Open-Label, Single-Arm Phase 3 Clinical Trial in First Quarter of 2017- Ra’anana, Israel, New York, NY, December 12, 2016: UroGen Pharma Ltd., a privately held, clinical stage biopharmaceutical company, today announced the acceptance of its … Continue reading

Posted in News | Leave a comment

UroGen Pharma Announces Agreement to License RTGel™ for Use with Neurotoxins to Allergan

RAANANA, Israel, Oct. 14, 2016 — UroGen Pharma (“UroGen”), a privately-held, clinical-stage biotechnology company,  announced today that it has completed an agreement to license worldwide rights to UroGen’s RTGelTM delivery system technology for use with neurotoxins to Allergan plc. RTGel™ … Continue reading

Posted in News | Leave a comment

UroGen Pharma Announces Three Data Presentations Related to its Clinical Stage Uro-Oncology Candidates at the American Urology Association’s 2016 Annual Meeting

New York, NY and Ra’anana, Israel, May 5th, 2016: UroGen Pharma, a clinical-stage biopharmaceutical company developing novel, locally-administered pharmaceutical solutions for urological pathologies with a focus on uro-oncology, announced today that the Company has been selected to present two oral/podium … Continue reading

Posted in News | Leave a comment

UroGen Pharma Strengthens Board of Directors and Senior Management Team

Appoints Stuart Holden, M.D., to its Board of Directors and Mark Schoenberg, M.D., as Medical Director New York, NY and Ra’anana, Israel, February 8, 2016: UroGen Pharma, Ltd. a clinical-stage biopharmaceutical company developing novel, locally-administered pharmaceutical solutions for urological pathologies with … Continue reading

Posted in News | Leave a comment

UroGen Pharma Strengthens Leadership Team and Expands Uro-Oncology Clinical Pipeline with Addition of TLR-7 Agonist Phase 2 Asset

New York, NY and Ra’anana, Israel, January 13, 2016: UroGen Pharma, Ltd. (formerly known as TheraCoat), a clinical-stage biopharmaceutical company developing novel, locally-administered pharmaceutical solutions for urological pathologies with a focus on uro-oncology, announced today the appointment of two key … Continue reading

Posted in News | Leave a comment

Urogen has been Granted Orphan Drug Designation from the US FDA for its Innovative Treatment of UTUC

Urogen Pharma, a clinical stage specialty pharmaceutical company focused on treatment of urological diseases, announced today that MitoGel, a sustained release formulation of Mitomcin C, has been granted orphan-drug designation by the U.S Food and Drug Administration (“FDA”) for the … Continue reading

Posted in News | Comments Off on Urogen has been Granted Orphan Drug Designation from the US FDA for its Innovative Treatment of UTUC

UroGen is recruiting clinical centers for the OLYMPUS trial for UTUC patients

UroGen Pharma is planning to start the OLYMPUS trial during 2016 and is looking for centers in US and Europe. The study will evaluate  the feasibility, safety, durability and ablative effect of MMC Mixed With TCGel in patients with Upper Tract Urothelial … Continue reading

Posted in News | Leave a comment

UroGen presented its Interstitial Cystitis safety and feasibility pilot study results during ICS 2014, Brazil

Dr Koby Stav from the Neurourology Division, Department of Urology, Assaf Harofeh Medical Center, presented the results of the study named “Safety and feasibility of intravesical instillation of botulinum toxin A in a novel hydrogel-based slow release delivery system in PBS/IC … Continue reading

Posted in News | Leave a comment